Virtue Diagnostics is a platform-based in vitro diagnostics (IVD) company focused on infectious disease, cancer, and chronic diseases. It provides affordable clinical solutions across all disease stages, including very early screening, initial diagnosis, treatment monitoring and minimal residual disease management. The company is led by CEO Johnson Zhang and is based in Singapore and Shanghai. Virtue's corporate and R&D headquarters are in Singapore, manufacturing is in Suzhou, China, and it operates a CRO/clinical lab in Beijing. In October 2022 the company raised $100M in a Series B to support its growth. Virtue intends to use the funds to bring its IVD products to selected emerging markets.

Total raised

$100M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2022